Sirolimus, also widely known as Rapamycin (CAS 53123-88-9), is a remarkable macrolide compound with profound medical significance. Initially isolated in 1972 from *Streptomyces hygroscopicus* found on Easter Island, this natural product was first explored for its antifungal properties. However, its true potential emerged with the discovery of its potent immunosuppressive and antiproliferative capabilities, leading to its approval for various critical therapeutic applications.

One of Sirolimus's primary indications is the prevention of organ transplant rejection, particularly in renal transplant recipients. Its unique advantage lies in its lower toxicity toward kidneys compared to conventional calcineurin inhibitors, making it a preferred option for long-term immunosuppression. It can be used alone or in conjunction with other immunosuppressants to achieve steroid-free regimens. While effective, careful patient monitoring is essential, as some transplant centers prefer to introduce it weeks or months post-transplant due to potential effects on wound healing.

Beyond transplantation, Sirolimus is also the first drug approved by the US Food and Drug Administration (FDA) for the treatment of lymphangioleiomyomatosis (LAM), a rare, progressive lung disease that predominantly affects women. Sirolimus blocks the mTOR signaling pathway, which is activated in LAM due to mutations in the tuberous sclerosis complex gene (TSC2), thus inhibiting the release of lymphangiogenic growth factors that drive the disease.

The antiproliferative effects of Sirolimus have also been harnessed in coronary stent coating. When applied to drug-eluting stents, it plays a crucial role in preventing restenosis (re-narrowing) of coronary arteries following balloon angioplasty, significantly reducing the need for repeat procedures. Additionally, Sirolimus is increasingly recognized for its efficacy in treating various vascular malformations and facial angiofibromas associated with tuberous sclerosis complex (TSC), by controlling tissue overgrowth disorders linked to inappropriate activation of the PI3K/AKT/mTOR pathway.

At its core, Sirolimus functions as a mammalian target of rapamycin (mTOR) kinase inhibitor. This mechanism allows it to reduce the sensitivity of T cells and B cells to interleukin-2 (IL-2), thereby inhibiting their activation and proliferation. The compound achieves this by binding to the cytosolic protein FK-binding protein 12 (FKBP12), and this complex then directly inhibits mTOR Complex 1 (mTORC1), a crucial pathway regulating cell growth and survival.

At NINGBO INNO PHARMCHEM CO.,LTD., we are committed to being a reliable manufacturer and supplier of high-quality Sirolimus powder (CAS 53123-88-9). We ensure that our Sirolimus meets stringent quality control standards, with a purity exceeding 99%. Our dedication to excellence ensures that pharmaceutical companies and research institutions can purchase this vital active pharmaceutical ingredient with confidence, enabling the development of life-saving medicines. We strive to offer a competitive price and efficient delivery, understanding the critical timelines in pharmaceutical production.

The versatility of Sirolimus extends beyond its established therapeutic uses into a broad spectrum of ongoing research. Its antiproliferative properties are being extensively investigated for potential roles in cancer therapy, with studies exploring its ability to enhance immune responses against tumors and inhibit tumor progression. Furthermore, Sirolimus has garnered significant attention in longevity research, showing promising results in extending lifespan in various model organisms by modulating the mTOR pathway. Its potential applications also span the treatment of SARS-CoV-2, atherosclerosis, lupus, lymphatic malformation, and graft-versus-host disease (GVHD), underscoring its broad biological impact and future therapeutic promise. Researchers looking to buy Sirolimus for innovative studies will find NINGBO INNO PHARMCHEM CO.,LTD. a dependable supplier.

Sirolimus (Rapamycin) continues to be an indispensable compound in modern medicine and a subject of intense scientific inquiry. NINGBO INNO PHARMCHEM CO.,LTD. is proud to be a trusted manufacturer of this critical pharmaceutical intermediate, dedicated to supporting global health and scientific advancement. For those seeking to purchase high-purity Sirolimus powder, our commitment to quality, competitive price, and reliable supply ensures you receive the best for your needs.